TCRX (STOCKS)
TScan Therapeutics, Inc. Common Stock
$0.934300
-0.038100 (-3.92%)
Prev close: $0.972400
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Gavin MacBeath
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $52.85M
- Employees
- 210
- P/E (TTM)
- -0.87
- P/B (TTM)
- 0.38
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
7
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.28 | $-0.30 | +0.0212 | +7.04% |
|
Jun 2025 (Q2)
|
$-0.28 | $-0.29 | +0.0062 | +2.17% |
|
Mar 2025 (Q1)
|
$-0.26 | $-0.29 | +0.0317 | +10.87% |
|
Dec 2024 (Q4)
|
$-0.30 | $-0.28 | -0.0208 | -7.45% |
Financial Statements
| Revenues | $8.42M |
| Benefits Costs and Expenses | $72.77M |
| Costs And Expenses | $154.06M |
| Operating Expenses | $157.09M |
| Research and Development | $123.47M |
| Other Operating Expenses | $29.53M |
| Operating Income/Loss | -$148.67M |
| Income/Loss From Continuing Operations After Tax | -$142.60M |
| Income/Loss From Continuing Operations Before Tax | -$64.35M |
| Interest Expense, Operating | $2.85M |
| Net Income/Loss | -$142.60M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$142.60M |
| Net Income/Loss Available To Common Stockholders, Basic | -$142.60M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.12 |
| Diluted Earnings Per Share | -$1.12 |
| Basic Average Shares | 132,703,376 |
| Diluted Average Shares | 132,703,376 |
| Assets | $262.23M |
| Current Assets | $188.17M |
| Noncurrent Assets | $74.06M |
| Fixed Assets | $9.30M |
| Other Non-current Assets | $64.76M |
| Liabilities | $118.20M |
| Current Liabilities | $29.21M |
| Accounts Payable | $6.35M |
| Wages | $5.76M |
| Other Current Liabilities | $17.10M |
| Noncurrent Liabilities | $89.00M |
| Long-term Debt | $32.41M |
| Other Non-current Liabilities | $56.58M |
| Equity | $144.02M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $144.02M |
| Liabilities And Equity | $262.23M |
| Net Cash Flow From Operating Activities | -$130.73M |
| Net Cash Flow From Operating Activities, Continuing | -$130.73M |
| Net Cash Flow From Investing Activities | $121.84M |
| Net Cash Flow From Investing Activities, Continuing | $121.84M |
| Net Cash Flow From Financing Activities | $45.28M |
| Net Cash Flow From Financing Activities, Continuing | $45.28M |
| Net Cash Flow | $36.39M |
| Net Cash Flow, Continuing | $36.39M |
| Comprehensive Income/Loss | -$142.60M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$142.60M |
| Other Comprehensive Income/Loss | -$72.66M |